What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

European Journal of Cancer

Volumn 45, Issue 17, 2009, Pages 2984-2991

  Aapro, Matti ^a   Barnadas, Agustí ^b   Leonard, Robert C ^c   Marangolo, Maurizio ^d   Untch, Michael ^e   Ukarma, Lidia ^f   Burger, Hans Ulrich ^f   Scherhag, Armin ^f,g   Osterwalder, Bruno ^f  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d Divisione Oncologia   (Italy)

^e Helios Klinikum   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anaemia; Breast cancer; Epoetin; Thrombovascular events

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALTEPLASE; ANTHRACYCLINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BEMIPARIN; CERTOPARIN; CLOPIDOGREL; DALTEPARIN; DEFIBROTIDE; DIPYRIDAMOLE; ENOXAPARIN; FLUINDIONE; HEMOGLOBIN; HEPARIN; HEPARIN CALCIUM; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RECOMBINANT ERYTHROPOIETIN; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; TAXANE DERIVATIVE; TICLOPIDINE; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BREAST CANCER; CANCER PATIENT; CARDIOVASCULAR RISK; CATHETER OCCLUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMORRHOID; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; THROMBOPHLEBITIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EPIDEMIOLOGIC METHODS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FIBRINOLYTIC AGENTS; HEMATINICS; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; THROMBOPHLEBITIS; THROMBOSIS;

EID: 70350578941     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.06.031     Document Type: Article

References (30)

1. Trousseau A. Phlegmasia alba dolens. In: Balliere J. (Ed). Clinique médicale de l'Hôtel-Dieu Paris. 2nd ed. (1865), JB Balliere & Fils, Paris, France 654-712
2. Kakkar A.K., Levine M., Pinedo H.M., Wolff R., and Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8 (2003) 381-388
3. Lee A.Y., and Levine M.N. Venous thromboemobolism and cancer: risk and outcomes. Circulation 107 Suppl. 1 (2003) 117-121
4. Bick R.L. Cancer-associated thrombosis. N Engl J Med 349 (2003) 109-111
5. Heit J.A., Silverstein M.D., Mohr D.N., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
6. Remiszewski P., Slodkowska J., Wiatr E., et al. Pulmonary thromboembolism as the main or secondary cause of death in patients treated for small cell lung cancer. Pneumonol Alerfol Pol 67 (1999) 470-476
7. Gezelius C., and Eriksson A. Neoplastic disease in a medicolegal autopsy material. A retrospective study in northern Sweden. Rechtsmed 101 (1988) 115-130
8. Ambrus J.L., Ambrus C.M., Mink I.B., and Pickern J.W. Causes of death in cancer patients. J Med 6 (1975) 61-64
9. Gao S., and Escalante C. Venous thromboembolism and malignancy. Expert Rev Anticancer Ther 4 2 (2004) 303-319
10. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
11. Gail M.H., Costantino J.P., Bryant J., et al. Weighing the risk and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91 21 (1999) 1829-1846
12. Levine M.N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in woman with stage II breasts cancer. N Engl J Med 318 7 (1988), 404-407
13. Goodnough L.T., Saito H., Manni A., Jones P.K., and Pearson O.H. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54 7 (1984) 1264-1268
14. Coiffier B., Boogaerts M., Aapro M., Hayward C., and Burger H.-U. Effect of treatment with epoetin beta on thromboembolic events in anemic patients with cancer: a meta-analysis. Support Cancer Ther 4 1 (2006) 49-55
15. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B., and Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Exporting Alfa Study Group. J Clin Oncol 19 (2001) 2865-2874
16. Vansteenkiste J., Pirker R., Massuti B., Barata F., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
17. Aapro M., Scherhag A., and Burger H.U. Effect of treatment with epoetin-β on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 99 (2008) 14-22
18. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anaemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
19. Rosenzweig M.Q., Bender C.M., Lucke J.P., Yasko J.M., and Brufsky A.M. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 27 (2004) 185-190
20. Bennett C.L., Silver S.M., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 8 (2008) 914-924
21. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. The Oncologist 13 3 (2008) 11-15
22. Bohlius J, Wilson J, Seidenfeld S, et al. Erythropoietin or darbepoetin for patients with (cochrane review). In: The cochrane library, issue 3. Chichester, UK: John & Sons Ltd.; 2006.
23. van Doormaal F.F., Büller H.R., and Middeldorp S. Development in antithrombotic therapy. Crit Rev Oncol Hematol 66 2 (2008) 145-154
24. Niers T.M., Klerk C.P., DiNisio M., et al. Mechanism of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 61 3 (2007) 195-207
25. Aapro M., Leonard R.C., Barnadas A., et al. Effect of once - weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline - and/or taxane-based chemotherapy: results of the breast cancer-anemia and the value of erythropoietin (BRAVE) study. J Clin Oncol 26 4 (2008) 592-598
26. Pober J.S. TNF as an activator of vascular endothelium. Ann Inst Pasteur Immunol 139 3 (1988) 317-323
27. Dvorak H.F. Thrombosis and cancer. Hum Pathol 18 3 (1987) 275-284
28. Tang Y.-D., Rinder H.M., and Katz S.D. Effects of recombinant human erythropietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial. Am Heart J 154 (2007) 494.e1-494.e7
29. Stohlawetz P.J., Dzirlo L., Hergovich N., et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95 (2000) 2983-2989
30. Fullmer A.C., and Miller R. Retrospective review of hemoglobin and/or hematocrit levels with occurrence of thrombosis in cancer patients treated with erythropoiesis stimulating agents. J Oncol Pharm Pract 00 (2009) 1-7